cancer
cell
tend
highli
depend
capdepend
translat
normal
tissu
thu
protein
involv
initi
capdepend
translat
emerg
potenti
anticanc
drug
target
capdepend
translat
initi
bind
factor
cap
domain
mrna
detail
xray
crystal
nmr
structur
avail
associ
capanalog
well
domain
initi
factor
review
summar
effort
design
potenti
antagonist
could
use
new
pharmacolog
tool
anticanc
agent
insight
drawn
studi
aid
design
futur
inhibitor
depend
translat
initi
ribosom
recruit
mrna
crucial
step
protein
synthesi
known
target
translat
control
eukaryot
cell
two
main
mechan
ribosom
recruit
capdepend
translat
cellular
mrna
use
standard
mode
translat
involv
assembl
preiniti
translat
complex
gpppx
cap
structur
gtp
mrna
x
nucleotid
ii
capindepend
translat
process
initi
direct
interact
translat
machineri
intern
ribosom
entri
site
ire
element
within
rna
mechan
use
plusstrand
viral
rna
sever
dozen
cap
eukaryot
mrna
possess
ire
untransl
region
utr
first
step
eukaryot
translat
involv
prepar
group
small
ribosom
subunit
fig
two
subunit
ribosom
tend
remain
associ
normal
physiolog
condit
though
studi
indic
presenc
heterogen
popul
particl
bind
initi
factor
subunit
howev
lead
disassembl
format
pool
small
ribosom
subunit
next
complex
bind
initi
trna
mettrnai
associ
complex
specif
site
bind
subunit
ribosomalbound
fig
recruit
small
ribosom
subunit
end
mrna
rate
limit
highli
regul
initi
eukaryot
protein
synthesi
process
includ
format
heterotrimer
translat
initi
complex
associ
gtp
cap
structur
mrna
complex
consist
mrna
capbind
protein
rnadepend
atpas
helicas
unwind
secondari
structur
mrna
forc
releas
bound
protein
mrna
end
scaffold
protein
serv
dock
function
assembl
complex
associ
ribosom
subunit
contact
adapt
complex
fig
activ
atpas
helicas
stimul
small
rnabind
protein
involv
ribosom
recruit
mrna
execut
bridg
function
mrna
ribosom
via
although
consensu
reach
regard
sequenc
event
lead
assembl
complex
mrna
cap
experiment
result
favor
model
interact
cap
structur
take
place
complex
assembl
ribosom
along
associ
initi
factor
scan
utr
encount
initi
codon
aug
cognat
fig
thereaft
ribosom
join
form
activ
ribosom
releas
subunit
bind
bind
complex
bind
mrna
complex
complex
assembl
limit
abund
cytoplasm
capbind
protein
specif
recogn
n
methyl
guanosinecap
end
mrna
kda
polypeptid
evolutionarili
conserv
protein
grow
bodi
experiment
evid
place
deregul
translat
causal
pathway
cancer
first
capdepend
translat
constitut
upregul
major
possibl
human
malign
overexpress
one
earli
event
breast
tumorigenesi
second
mous
tumor
model
confirm
overexpress
suffici
transform
cell
third
genet
intervent
revers
transform
phenotyp
cancer
cell
normal
deregul
translat
associ
sustain
regress
xenograft
tumor
togeth
find
suggest
regul
initi
step
protein
synthesi
contribut
significantli
cancer
genesi
wide
rang
malign
becom
highli
depend
hyperactiv
translat
thu
protein
involv
regul
capdepend
translat
could
consid
anticanc
target
review
focu
biolog
role
biochem
structur
characterist
one
protein
addit
survey
major
advanc
challeng
futur
direct
design
develop
antagonist
potenti
anticanc
target
accord
one
formul
cellular
mrna
categor
two
group
strong
mrna
rel
short
unstructur
utr
weak
mrna
lengthi
highli
structur
utr
signific
differ
two
group
mrna
weak
mrna
much
sensit
avail
weak
mrna
usual
encod
growth
surviv
factor
whose
level
express
good
indic
experiment
cancer
model
activ
disproport
dramat
stimul
translat
limit
defin
set
mrna
encod
cancerrel
protein
control
cell
prolifer
viabil
fig
function
therefor
oncogen
overexpress
target
cell
physiolog
condit
avail
tightli
regul
neg
regul
protein
normal
physiolog
condit
bound
famili
inhibitori
protein
sequest
occupi
bind
site
fig
upon
trophic
stimul
phosphoryl
multipl
site
rasextracellular
signalregul
kinas
raserk
kinaseatk
signal
pathway
phosphoryl
releas
therebi
enabl
assembl
complex
follow
deliveri
mrna
complex
support
conclus
demonstr
treatment
cancer
cell
rapamycin
inhibitor
mtor
result
dephosphoryl
cancer
cell
growth
inhibit
fig
hypophosphoryl
bind
tightli
form
trimerthu
inhibit
capdepend
translat
initi
taken
togeth
result
demonstr
antagon
format
potenti
anticanc
approach
moreov
antagonist
format
inhibit
translat
mrna
equal
rather
antagon
disproportion
effect
translat
mrna
depend
activ
gener
oncogen
mrna
fall
categori
display
differenti
sensit
antagon
addit
inhibit
capdepend
translat
minim
impact
intern
ribosom
entri
site
ire
mediat
translat
confer
select
although
report
suggest
inhibit
apoptosi
translat
hypoxia
cancer
cell
involv
iresmedi
translat
topic
beyond
scope
review
addit
phosphoryl
also
found
phosphoryl
cancer
cell
nevertheless
import
phosphoryl
statu
context
cancer
remain
activ
area
investig
phosphoryl
usual
ser
mediat
map
kinaseinteract
protein
turn
activ
rasregul
mapkerk
kinasesign
pathway
process
facilit
bind
event
bring
proxim
raptor
gbl
mtor
complex
mediat
phosphoryl
rapamycin
would
bind
mtor
dephosphoryl
hypophosphoryl
form
bind
tightli
thu
inhibit
capdepend
translat
initi
kinas
phosphoryl
associ
concomit
activ
capdepend
translat
express
transform
phenotyp
howev
mechan
phosphoryl
lead
increas
translat
role
phosphoryl
cancer
initi
mainten
remain
controversi
promot
tumorigenesi
must
phosphoryl
ser
indic
mechan
translat
activ
phosphoryl
directli
associ
capbind
function
increas
level
phosphoryl
detect
cancer
broad
spectrum
cancer
cell
line
activ
phosphoryl
requir
overexpress
cooper
deregul
myc
promot
mous
lymphomagenesi
togeth
data
support
specul
increas
phosphoryl
may
cancer
pathway
howev
neither
tumor
progress
aggress
correl
level
phosphoryl
find
indic
role
phosphoryl
oncogenesi
requir
investig
xray
nuclear
magnet
reson
nmr
structur
capderiv
analog
guanosin
diphosph
gdp
gtp
gpppa
gpppg
determin
reveal
cap
nucleotid
resid
concav
surfac
protein
fig
specif
guanosin
cap
structur
achiev
intercal
nucleobas
two
tryptophan
residu
via
interact
hydrogen
bond
backbon
posit
two
hbond
posit
nh
carbonyl
group
posit
charg
region
capbind
pocket
phosphat
unit
interact
nearbi
residu
via
coulomb
interact
contribut
kcalmol
respect
toward
total
bind
energi
wagner
cowork
solv
solut
structur
yeast
complex
gdp
nmr
almost
time
crystal
structur
mous
solv
two
structur
similar
ident
cap
analog
gdp
structur
found
sandwich
side
chain
two
tryptophan
residu
narrow
hydrophob
cleft
fig
differ
includ
follow
two
helic
yeast
report
crystal
structur
mous
strand
slightli
longer
mous
capbind
site
orient
two
tryptophan
side
chain
entir
opposit
yeast
comparison
mous
solv
structur
differ
speci
elucid
interact
cap
could
import
understand
mechan
translat
initi
besid
sever
protein
recogn
mrna
cap
mainli
cation
interact
usual
term
protein
fact
well
character
studi
member
protein
famili
protein
famili
also
includ
also
known
three
protein
exhibit
much
weaker
affin
cap
addit
vaccinia
viru
capmodifi
enzym
scaveng
mrnadecap
enzym
dcp
also
undergo
interact
cap
structur
biolog
studi
protein
adopt
bind
mode
similar
cap
might
facilit
develop
druglik
inhibitor
interact
cap
analog
studi
extens
equilibrium
kinet
studi
reli
rational
intrins
fluoresc
origin
tryptophan
decreas
upon
cap
bind
method
evalu
antagonist
bind
also
develop
includ
surfac
plasmon
reson
spr
isotherm
titrat
calorimetri
nmr
previou
studi
led
propos
twostep
bind
mechan
gpppg
complex
form
first
step
accompani
reduc
fluoresc
follow
presum
complex
reorgan
second
step
even
lower
fluoresc
scheme
first
step
domin
ligand
bind
via
triphosph
moieti
basic
residu
second
step
bind
g
base
hydrophob
tryptophanbind
pocket
thought
result
decreas
fluoresc
nevertheless
kinet
studi
cap
analog
bind
yield
consist
mechanist
conclus
report
rate
constant
associ
k
rate
constant
dissoci
k
vari
much
two
three
order
magnitud
better
understand
interact
mechan
rhoad
cowork
carri
systemat
studi
cap
analog
bind
surprisingli
support
onestep
bind
mechan
stop
flow
experi
carri
pseudo
firstord
condit
vari
ionic
strength
rhoad
cowork
found
k
valuebut
k
valuefor
gpppg
bind
ionic
strength
depend
valu
k
rang
mm
kcl
obtain
k
rang
scheme
rel
high
k
valu
consist
rapid
equilibrium
process
k
valu
calcul
kinet
constant
rang
depend
ionic
strength
k
three
fivefold
higher
obtain
equilibrium
method
rational
discrep
propos
beyond
note
differ
protein
prepar
methodolog
rhoad
cowork
suggest
appar
kinet
mechan
cap
bind
depend
concentr
concentr
limit
stop
flow
studi
data
found
fit
well
one
exponenti
function
consist
simpl
onestep
associ
capbind
process
scheme
howev
concentr
gpppg
limit
concentr
vari
stop
flow
data
better
fit
twostep
bind
scheme
fast
phase
slow
phase
observ
amplitud
slow
phase
exhibit
depend
concentr
rhoad
cowork
hypothes
preexist
equilibrium
step
like
respons
observ
slow
phase
hypothes
concentr
increas
presenc
inact
dimmer
andor
oligom
may
account
observ
slow
phase
sinc
report
phosphoryl
enhanc
protein
synthesi
rhoad
cowork
also
determin
rate
constant
cap
bind
phosphoryl
p
transient
state
kinet
result
suggest
phosphoryl
decreas
k
mm
kcl
effect
mm
kcl
similar
nonphosphoryl
data
best
fit
singleexponenti
instead
doubleexponenti
function
cap
analog
concentr
valu
k
p
rang
valu
k
rang
k
valu
calcul
kinet
data
cap
analog
shown
twofold
higher
affin
p
except
valu
determin
highest
kcl
concentr
mm
addit
similar
kinet
valu
deriv
k
valu
found
approxim
fivefold
greater
valu
determin
equilibrium
method
sinc
studi
cap
bind
perform
monoor
dinucleotid
cap
analog
rhoad
cowork
also
carri
studi
physiolog
relev
ligand
cap
oligoribonucleotid
oligonucleotid
contain
antirevers
cap
analog
arca
gpppg
ensur
cap
correct
orient
previou
studi
interact
cap
oligonucleotid
use
mixtur
normal
cap
reversecap
oligoribonucleotid
bind
bind
affin
gpppg
gpppg
found
nearli
ident
determin
fluorescencequench
experi
bind
affin
cap
oligonucleotid
found
higher
arca
oligonucleotid
high
ionic
strength
larg
due
lower
k
valu
lower
ionic
strength
instanc
modest
differ
affin
two
oligo
either
p
observ
result
stoppedflow
kineticbind
studi
cap
oligonucleotid
suggest
onestep
bind
process
decreas
bind
affin
high
ionic
strength
mm
kcl
p
cap
analog
arca
fig
author
hypothes
pronounc
increas
affin
cap
oligonucleotid
may
result
addit
stabil
interact
form
low
ionic
strength
larger
ligand
sinc
sever
basic
amino
acid
residu
locat
surfac
near
capbind
side
later
surfac
groov
polynucleotid
chain
mrna
conceiv
could
found
possibl
addit
interact
occur
polynucleotid
chain
basic
side
chain
well
establish
bind
cap
mrna
also
assembl
sever
studi
report
cap
bind
modul
interact
basi
assumpt
support
sever
line
evid
ultraviolet
radiat
uv
crosslink
recombin
murin
chloramphenicol
acetyltransferas
mrna
markedli
enhanc
presenc
human
affin
fulllength
recombin
human
fluoresc
label
cap
analog
antm
gtp
enhanc
twofold
presenc
acid
peptid
bear
consensusbind
sequenc
human
gtpsepharos
pulldown
assay
suggest
affin
fulllength
recombin
yeast
gtp
shortcap
rna
increas
presenc
fulllength
recombin
yeast
contrast
studi
suggest
minim
impact
cap
bind
goss
cowork
found
littl
differ
bind
affin
tissuederiv
human
rabbit
rabbit
globin
mrna
moreov
presenc
amino
acid
peptid
contain
motif
mammalian
littl
influenc
bind
affin
recombin
murin
cap
analog
addit
crystal
structur
murin
complex
amino
acid
peptid
found
isomorph
complex
better
understand
effect
bind
cap
rhoad
cowork
carri
seri
transient
state
kinet
studi
human
gpppg
interact
human
bind
peptid
util
stop
flow
fluorescencequench
method
well
spr
result
suggest
affect
rate
constant
associ
dissoci
gpppg
bind
gpppg
complex
yield
k
valu
k
valu
fig
reaction
valu
within
experiment
error
differ
significantli
valu
k
k
determin
absenc
fig
reaction
rhoad
cowork
conclud
higher
affin
cap
rna
format
complex
proce
sequenti
random
kinet
mechan
thu
preferenti
pathway
format
complex
evid
implic
complex
tumorigenesi
develop
anticanc
therapi
begun
attract
attent
effort
larg
focus
disrupt
bind
cap
mrna
integr
enzym
activ
year
sever
nucleosid
nucleotid
analog
deriv
gtp
synthes
evalu
tool
capabl
modul
translat
initi
gener
inhibit
bind
cap
mrna
specif
darzynkiewicz
cowork
design
synthes
variou
cap
analog
includ
modif
posit
guanin
moieti
phosphat
moieti
ribos
ring
fig
sinc
aryl
substitut
shown
increas
bind
affin
studi
therefor
focus
util
synthet
nucleotid
deriv
guanosin
monophosph
bn
gmp
block
bind
mrna
cap
recent
crystal
structur
compar
complex
bn
gmp
fig
bn
gmp
fig
pf
bn
gmp
fig
shown
capbind
site
inher
flexibl
capabl
conform
chang
upon
bind
n
benzyl
mononucleotid
cap
analog
indol
side
chain
flip
allow
bulkier
benzyl
group
pack
hydrophob
caviti
still
maintain
ring
stack
hydrogen
bond
necessari
effici
interact
analog
residu
capbind
site
gain
bind
affin
due
placement
n
benzyl
substitu
hydrophob
pocket
dorsal
tryptophan
clamp
hydroxyl
group
cap
analog
interact
remain
solvent
expos
examin
role
ribos
ring
conform
constrain
isopropylidin
group
posit
fig
shown
enhanc
potenc
cap
deriv
twofold
compar
one
hydroxyl
free
ribos
ring
unconstrain
highli
predict
consist
three
dimension
quantit
structureact
relationship
model
deriv
combinatori
librari
bn
gmp
analog
pinpoint
sever
key
interact
involv
cap
bind
effect
cellfre
system
efficaci
bn
gmp
cell
poor
due
low
intracellular
uptak
one
approach
improv
vivo
activ
develop
stabl
cellperm
prodrug
enzymat
chemic
convert
activ
speci
phosphoramid
special
interest
purpos
consid
gener
high
water
solubl
low
nonexist
toxic
high
stabil
fact
success
exampl
applic
antivir
anticanc
purpos
recent
work
wagner
cowork
led
develop
novel
class
histidin
triad
nucleotid
bind
protein
hint
depend
pronucleotid
interfer
epithelialtomesenchym
transit
emt
key
translat
regul
step
develop
epitheli
cancer
well
patholog
tissu
fibrosi
neg
regul
associ
cap
compound
fig
bn
gmpderiv
phosphoramid
potent
inhibit
dosedepend
manner
capdepend
translat
zebrafish
embryo
without
caus
development
abnorm
addit
inhibit
capdepend
translat
without
caus
disturbanceon
cell
divis
develop
significantli
toxic
prevent
trigger
emt
zebrafish
ectoderm
explant
metabol
studi
whole
zebra
fish
lysat
confirm
convert
activ
compon
bn
gmp
rapidli
presum
zebra
fish
hint
presenc
hint
activ
earli
eightcel
stage
recent
establish
thu
demonstr
possibl
role
earli
stage
embryogenesi
first
nontox
small
molecul
abl
inhibit
emt
repres
success
util
prodrug
strategi
intracellular
releas
bn
gmp
result
inhibit
capdepend
translat
ribavirin
fig
propos
antagonist
potenti
base
proton
state
posit
charg
thu
similar
gtp
capabl
form
cation
interact
capbind
site
tryptopan
clamp
clinic
ribavirin
use
treatment
viral
infect
lassa
fever
viru
respiratori
syncyti
viru
hepat
c
viru
sever
acut
respiratori
syndrom
coronaviru
ribavirin
phosphoryl
cellular
kinas
vivo
ribavirin
triphosph
rtp
major
intracellular
metabolit
still
clear
account
ribavirin
antivir
activ
though
differ
mechan
suggest
inhibit
inosin
monophosph
dehydrogenas
incorpor
rna
viru
mutagen
templat
incorpor
cytidin
uridin
inhibit
viral
rna
cap
studi
also
suggest
ribavirin
strongli
inhibit
prolifer
cell
infect
dna
rna
virus
consid
possibl
identifi
mechan
ribavirin
mutual
exclus
may
inde
cooper
result
report
efficaci
reason
posit
mechan
ribavirin
involv
modul
translat
along
line
kentsi
cowork
report
direct
bind
ribavirin
appar
k
vitro
use
fluorescencequench
assay
ribavirin
analog
contain
uncharg
moieti
fail
bind
significantli
demonstr
rtp
gtp
bound
nearli
equal
affin
k
use
gsepharos
affin
chromatographi
determin
rtp
compet
g
bind
appar
inhibit
constant
k
similar
gtp
furthermor
ribavirin
found
disrupt
translat
mrna
regul
posttranscript
ribavirin
treatment
caus
reduc
level
cyclin
appar
ec
effect
concentr
need
reduc
level
cyclin
rel
control
also
show
ribavirin
potent
suppress
oncogen
transform
nih
cell
ec
treatment
ribavirin
signific
suppress
tumor
growth
mous
model
human
squamou
cell
carcinoma
recent
demonstr
contrast
yan
cowork
report
chemic
crosslink
assay
rtp
impair
abil
interact
cap
mrna
result
confirm
independ
capaffin
chromatographi
experi
demonstr
rtp
unabl
block
bind
gtp
sinc
effect
activ
cap
analog
evalu
inhibit
capdepend
translat
author
also
use
translat
extract
determin
whether
rtp
could
inhibit
capdepend
protein
synthesi
neither
gdp
rtp
affect
synthesi
either
renilla
luciferas
capdepend
firefli
luciferas
capindepend
synthesi
firefli
luciferas
inhibit
gdp
dosedepend
manner
kentsi
cowork
rebut
yan
cowork
suggest
bind
cap
highli
depend
solut
condit
argu
chang
ionic
strength
ph
temperatur
could
result
variat
sever
order
magnitud
capbind
affin
kentsi
cowork
repeat
affin
chromatographi
experi
provid
use
publish
condit
compar
use
yan
cowork
found
micromolar
concentr
rtp
compet
bind
contrast
rtp
fail
compet
gtp
bind
protocol
yan
cowork
use
thu
conclud
report
figur
structur
ribavirin
failur
ribavirin
bind
vitro
yan
cowork
probabl
result
differ
experiment
solut
condit
regard
vitro
translat
experi
yan
cowork
kentsi
cowork
argu
cell
extract
may
properli
reflect
condit
live
cell
reason
kentsi
cowork
emphas
import
assess
ribavirin
like
compound
function
vivo
order
determin
physiolog
relev
interact
kentsi
cowork
also
provid
direct
observ
specif
bind
ribavirin
use
mass
spectrometri
confirm
specif
bind
independ
westman
cowork
corrobor
find
yan
cowork
intrigu
kentsi
work
westman
cowork
test
ribavirin
rtp
dinucleotid
rpppg
abil
inhibit
translat
vitro
explor
possibl
intrins
relat
design
intend
determin
whether
ribavirincontain
analog
could
substitut
natur
cap
incorpor
mrna
surprisingli
vitro
translat
assay
suggest
ribavirincontain
compound
inhibit
translat
concentr
convent
cap
analog
could
effect
block
capdepend
translat
though
inhibit
observ
high
concentr
millimolar
howev
work
suggest
inhibit
effect
high
concentr
inconsist
action
block
experiment
also
exclud
possibl
could
lead
poor
translat
activ
metabol
instabl
compound
translat
system
failur
cap
incorrect
orient
furthermor
independ
fluoresc
titrat
experi
suggest
low
bind
affin
ribavirin
deriv
recombin
murin
human
recombin
nuclear
capbind
complex
two
four
order
magnitud
lower
valu
true
cap
analog
therefor
hypothes
guanin
rather
triazol
moieti
penetr
bind
surfac
case
rpppg
take
evid
togeth
conclud
ribavirin
structur
function
mimic
guanosin
moieti
translat
vitro
even
though
ribavirin
confirm
translat
inhibit
effect
vivo
point
view
manyif
allof
discrep
larg
due
differ
experiment
method
condit
field
would
greatli
advanc
investig
would
agre
establish
systemat
standard
set
assay
proofofprincipl
clinic
trial
ribavirin
recent
report
acut
myelogen
leukemia
patient
clinic
respons
ribavirin
correl
reduc
express
reloc
cytoplasma
find
seem
suggest
ribavirin
inde
promis
anticanc
drug
candid
function
least
part
inhibitor
possibl
direct
inhibitor
complex
assembl
play
pivit
role
regul
gene
express
stage
translat
initi
interrupt
small
molecul
would
establish
possibl
new
strategi
cancer
therapi
complex
regul
bind
bind
site
result
suggest
increas
level
tumorsuppressor
activ
proteinprotein
interfac
typic
contain
hot
spot
compact
region
conserv
residu
signific
proteinprotein
bind
thu
provid
target
develop
small
molecul
inhibitor
proteinprotein
interact
high
throughput
screen
compound
librari
appli
identifi
small
molecul
modul
translat
initi
high
throughput
fluoresc
polarizationbind
assay
establish
identifi
small
molecul
specif
disrupt
interact
peptid
contain
sequenc
kytydelfqlp
k
synthes
label
r
jia
et
al
fluorescein
tag
principl
high
throughput
screen
identifi
compound
displac
fluoresceinlabel
peptid
detect
fluoresc
polar
librari
compound
chembridg
diverset
e
screen
small
molecul
identifi
competit
inhibitor
peptid
bind
similarli
activ
analog
also
synthes
fig
caus
displac
dosedepend
manner
inhibit
capdepend
translat
vitro
renilla
luciferas
report
assay
system
neither
compound
inhibitori
effect
capindependentiresdriven
translat
similar
effect
observ
sever
mammalian
cancer
cell
line
treat
treatment
caus
cell
death
jurkat
cell
line
inhibit
prolifer
lung
cancer
cell
sinc
compet
bind
would
expect
inhibit
bind
howev
vitro
cancer
cell
line
experi
caus
signific
appar
increas
amount
bound
shown
result
gtp
pulldown
assay
one
possibl
explan
displac
clear
dock
site
sinc
probabl
occupi
larger
footprint
though
bind
overlap
site
though
discov
small
molecul
inhibitor
disrupt
interact
recent
studi
fan
et
al
reveal
novel
biolog
function
sensit
human
lung
cancer
cell
augment
tumor
necrosi
factorrel
apoptosisinduc
ligand
trail
mediat
apoptosi
independ
capdepend
translat
death
ligand
trail
bind
receptor
therefor
mediat
apoptosi
preferenti
transform
malign
cell
normal
cell
therefor
trail
attract
research
interest
cancer
therapeut
target
current
recombin
human
trail
test
clinic
trial
anticanc
agent
nevertheless
certain
cancer
cell
intrins
resist
traildeath
receptorinduc
apoptosi
thu
certain
sensit
agent
use
combin
trail
enhanc
trailbas
cancer
therapi
addit
panner
et
al
defin
translat
control
new
mechan
mtor
pathway
play
import
role
control
death
ligandinduc
apoptosi
trail
sensit
discov
trail
resist
glioblastoma
multiform
consequ
overexpress
short
isoform
cflice
inhibitori
protein
flip
flip
express
translat
upregul
activ
mtor
pathway
kinas
activ
drive
associ
flip
mrna
translat
polyribosom
complex
understand
linkag
death
ligandinduc
apoptosi
translat
control
fan
et
al
attempt
resolv
intrins
trail
resist
certain
cancer
cell
test
effici
trail
alon
combin
human
lung
cancer
cell
fan
et
al
found
alon
induc
apoptosi
human
lung
cancer
cell
also
cooper
trail
enhanc
apoptosi
expect
singl
agent
inhibit
complex
format
inhibit
cell
growth
induc
apoptosi
human
lung
cancer
cell
moreov
combin
trail
much
effect
either
trail
alon
term
kill
human
lung
cancer
cell
detail
mechanist
studi
fan
et
al
suggest
increas
express
chopdepend
mechan
chop
refer
chemotherapi
regim
consist
cyclophosphamid
hydroxydaunorubicinm
oncovin
prednisolon
reduc
cflip
level
ubiquitinproteasomemedi
degrad
often
involv
druginduc
sensit
traildeath
receptorinduc
apoptosi
interestingli
neither
knockdown
sirna
rapamycin
increas
express
reduc
cflip
enhanc
trailinduc
apoptosi
cancer
cell
test
suggest
modul
cflip
enhanc
trailinduc
apoptosi
independ
inhibit
capdepend
translat
thu
suggest
biolog
activ
compound
least
partial
depend
signific
target
mechan
anoth
small
molecul
inhibitor
fig
disrupt
interact
recent
discov
pelleti
cowork
found
screen
librari
compound
use
time
resolv
tr
fluoresc
reson
energi
transfer
fret
base
assay
molecular
model
bind
suggest
potenti
mechan
inhibit
interact
either
possibl
bind
four
shallow
pocket
overlap
site
western
blot
analysi
confirm
inde
block
format
complex
inhibit
r
jia
et
al
figur
peptid
agonist
bind
deriv
conserv
residu
protein
import
bind
capdepend
translat
dosedepend
manner
ic
affect
capindepend
translat
vitro
translat
assay
addit
inhibit
protein
synthesi
vivo
hela
cell
without
greatli
affect
rna
dna
level
result
demonstr
enhanc
amount
free
reduc
amount
also
reduc
concentr
translat
activ
thu
function
small
molecul
mimic
significantli
pelleti
cowork
demonstr
capabl
revers
tumor
chemoresist
genet
engin
lymphoma
mous
model
treatment
mice
bear
pten
doxorubicin
extend
tumorfre
remiss
day
control
set
treat
doxorubicin
examin
tumor
reveal
anim
treat
doxorubicin
exhibit
increas
number
apoptot
cell
decreas
level
antiapoptot
protein
compar
anim
dose
doxorubicin
taken
togeth
result
demonstr
excit
new
small
pharmacophor
potenti
use
develop
addit
chemic
genet
probe
drug
target
interfac
anoth
strategi
develop
naora
cowork
use
peptid
interfer
interact
sinc
phosphoryl
mtor
releas
bind
peptid
might
bind
therefor
prevent
bind
synthes
peptid
contain
residu
fuse
peptid
analog
gonadotropinreleas
hormon
gnrh
gnrh
fig
util
fusion
peptid
gnrh
agonist
mainli
base
follow
consider
overexpress
epitheli
ovarian
cancer
endocrin
cancer
suit
target
strategi
gnrh
agonist
possess
capabl
facilit
cellular
uptak
peptid
sinc
effici
intern
receptormedi
endocytosi
small
size
gnrh
agonist
insur
interfer
bind
peptid
found
peptid
bound
inhibit
capdepend
translat
multipl
cell
line
express
gnrh
agonist
alon
bind
addit
fusion
peptid
contain
mutat
three
critic
residu
bind
inhibit
capdepend
translat
naora
cowork
found
peptid
inhibit
growth
gnrhposit
cell
dosedepend
manner
wherea
inhibit
observ
cell
lack
express
significantli
treatment
femal
nude
mice
bear
ip
ovarian
tumor
xenograft
fusion
peptid
suggest
reduc
tumor
burden
compar
gnrh
truncat
peptid
alon
salin
although
author
could
total
exclud
possibl
peptid
might
inhibit
growth
part
mechan
unrel
inhibit
activ
approach
result
potent
compound
abl
target
epitheli
ovarian
cancer
intriguingli
approach
naora
cowork
gener
applic
design
tissuespecif
agonist
substitut
gnrn
peptid
agonist
tissuespecif
target
peptid
graff
cowork
provid
first
vivo
evid
cancer
may
suscept
inhibit
normal
cell
use
aso
administr
aso
substanti
explor
pharmacolog
tool
therapeut
recogn
hybrid
target
mrna
watsoncrick
base
pair
follow
rnase
hmediat
rna
destruct
sever
aso
design
target
growth
factor
kinas
etc
cancer
therapeut
earlier
gener
aso
howev
innat
defect
util
system
therapi
resist
nucleas
tissu
stabil
issu
second
gener
aso
contrast
engin
accommod
issu
incorpor
modif
omethyl
omethoxyethyl
moe
clinic
trial
current
process
modif
result
threeto
tenfold
increas
biolog
activ
alter
pharmacokinet
properti
increas
nucleas
resist
tissu
stabil
graff
cowork
design
aso
capabl
target
murin
human
evalu
vivo
effect
reduct
human
xenograft
tissu
normal
mous
tissu
mrna
level
protein
level
cultur
human
cancer
cell
suppress
treatment
aso
four
aso
select
inhibit
cultur
human
murin
cell
sequenc
follow
moemodifi
base
underlin
aso
reduc
rna
express
level
concentr
nm
human
tumor
cell
murin
endotheli
cell
aso
also
substanti
decreas
express
mani
malignancyrel
protein
includ
oncogen
cmyc
cyclin
antiapoptot
protein
angiogenesi
factor
vegf
inhibitor
apoptosi
protein
survivin
decreas
observ
hr
transfect
along
decreas
express
studi
consist
previou
hypothesi
alter
level
select
chang
express
growth
regulatori
protein
contrast
alter
level
limit
effect
global
protein
synthesi
incorpor
total
protein
reduc
cell
transfect
nm
aso
compar
mocktransfect
control
similarli
hela
cell
incorpor
total
protein
margin
reduc
transfect
nm
rna
express
decreas
furthermor
system
administr
decreas
express
xenograft
tumor
suppress
tumor
growth
angiogenesi
dose
reveal
reduct
express
breast
cancer
xenograft
tumor
similarli
reduct
express
observ
human
prostat
cancer
xenograft
mice
dose
mgkg
thrice
weekli
month
significantli
level
decreas
normal
mous
tissu
without
obviou
toxic
notic
chang
liver
weight
aso
preferenti
accumul
spleen
weight
bodi
weight
liver
transaminas
level
asotr
nontumor
bear
mice
although
express
level
rna
decreas
tumorspecif
rnai
target
recent
shown
downregul
gene
express
effect
specif
led
breast
carcinoma
cell
apoptosi
induct
tumor
growth
suppress
enhanc
chemosensit
cisplatin
vitro
vivo
collect
result
suggest
promis
therapeut
target
human
malign
treatment
regul
capdepend
translat
import
contributor
tumorgenesi
consequ
member
translat
initi
complex
propos
potenti
anticanc
drug
target
protein
initi
complex
format
mrna
cap
ratelimit
factor
capdepend
translat
initi
necessari
regul
tumor
cell
apoptosi
prolifer
potenti
metastasi
sever
approach
attempt
block
function
tri
year
small
molecul
inhibitor
disrupt
interact
cap
analog
directli
target
capbind
site
although
avail
nmr
xray
structur
greatli
enhanc
possibl
structurebas
inhibitor
design
antagonist
enthusiasm
approach
temper
substanti
structur
flexibl
use
aso
reduc
express
level
prove
use
advanc
clinic
trial
prostat
cancer
patient
nevertheless
despit
tantal
promis
target
cancer
capdepend
translat
understand
role
well
member
complex
cancer
cell
oncogen
express
still
infanc
success
studi
depend
develop
use
chemic
biolog
tool
subset
may
show
potenti
anticanc
drug
lead
